Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis (Euronext Growth: CLLS) published its monthly report on share capital and voting rights as of March 31, 2026. The company reports 100,590,994 total shares and 106,001,228 total voting rights (ISIN: FR0010425595).

For questions, investor and media contacts are provided by the company.

News Market Reaction – CLLS

+5.65%

+5.65% Session close to close

In the Apr 8 session, CLLS gained 5.65%, reflecting a notable positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +5.7% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +5.7% in the session following this news. A strong positive reaction aligns with the company’s established pattern of transparent capital-structure reporting. This notice simply confirms 100,590,994 shares and 106,001,228 voting rights as of 03/31/2026. Any outsized move would have come against relatively light pre-news volume and within a stock already trading below its $3.44 200-day average, suggesting investors weighed this routine disclosure against broader biotech sentiment and existing financing flexibility under the active F-3 shelf.

Key Figures

Total shares: 100,590,994 Total voting rights: 106,001,228 Reference date: 03/31/2026

3 metrics

Total shares 100,590,994 Total number of shares in the capital as of 03/31/2026

Total voting rights 106,001,228 Total number of company voting rights as of 03/31/2026

Reference date 03/31/2026 Date of reported share capital and voting rights

Historical Context

5 past events · Latest: Mar 19 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 19	Full-year earnings	Neutral	-4.0%	Reported 2025 financials, clinical progress and cash runway into H2 2027.
Mar 12	Earnings date set	Neutral	+2.7%	Announced timing of Q4 and full-year 2025 results and investor call.
Mar 04	Monthly capital update	Neutral	-2.4%	Disclosed total shares and voting rights as of 02/28/2026.
Feb 04	Monthly capital update	Neutral	-1.1%	Reported share count and voting rights as of 01/31/2026.
Jan 08	Strategy & catalysts	Neutral	-1.6%	Outlined 2026 strategy, key trials, and expected clinical milestones.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent news, including monthly capital reports and strategic updates, has often been followed by relatively small single-day moves, with no clear positive or negative pattern.

Recent Company History

Over the last few months, Cellectis has combined routine disclosures with major strategic updates. On Jan 8, 2026, it outlined its 2026 CAR-T strategy and expected catalysts. Monthly share capital and voting-rights notices were issued on Jan 31 and Feb 28, 2026, similar to today’s update. On Mar 19, 2026, the company reported full-year 2025 results, highlighting $79.6M revenue and cash runway into H2 2027. Today’s release continues that pattern of regular capital-structure transparency.

Key Terms

isin code, voting rights

2 terms

isin code financial

"Listing market: Euronext Growth ISIN code: FR0010425595"

An ISIN code is a unique identifier for a specific financial asset, like a stock or bond, similar to a product's barcode. It helps investors, traders, and banks quickly and accurately find and track that asset across different markets worldwide. This makes buying, selling, and managing investments more organized and reliable.

voting rights regulatory

"Total number of voting rights"

Voting rights are the ability of shareholders to have a say in important company decisions, like choosing leaders or approving big changes. They matter because they give owners a voice in how the company is run, similar to how voters influence elections, ensuring the company acts in shareholders’ interests.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

(Article 223-16 of General Regulation of the French financial markets authority)

PARIS, April 07, 2026 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
03/31/2026	100,590,994	106,001,228

For further information on Cellectis, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:
Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com 

Attachments

• Voting_Rights_PR_March_2026_EN

FAQ

How many shares did Cellectis (CLLS) report on March 31, 2026?

Cellectis reported 100,590,994 total shares as of March 31, 2026. According to the company, this figure reflects the total number of shares in the capital for that reporting date and is published under applicable market regulation.

What were the total voting rights for Cellectis (CLLS) on March 31, 2026?

The company reported 106,001,228 total voting rights as of March 31, 2026. According to the company, this count represents all exercisable voting rights tied to the reported share capital on that date.

Where is Cellectis (CLLS) listed and what is its ISIN code?

Cellectis is listed on Euronext Growth and uses ISIN FR0010425595. According to the company, the listing market and ISIN are provided in the monthly disclosure of share capital and voting rights.

Who should investors contact for more information about Cellectis (CLLS) share capital?

Investors can contact Arthur Stril, Chief Financial Officer & Chief Business Officer, at the provided investor relations email. According to the company, investor and media contacts are listed for further queries.

How often does Cellectis (CLLS) publish share capital and voting rights information?

Cellectis publishes monthly information on share capital and voting rights under market regulations. According to the company, this disclosure is part of routine regulatory reporting and includes the reporting date and totals.